Fate Therapeutics Extends Runway to 2027 with $205M Cash and 30% Cost Cut
Fate Therapeutics ended 2025 with $205 million in cash and investments and cut operating expenses by 30%, extending its runway to year-end 2027. The company expanded its FT819 Phase 1 trial to 16 sites treating 20 patients with outpatient dosing and saw FT836 deliver over 50% CEA reduction in colorectal cancer.
1. Financial Results and Runway
Fate Therapeutics ended 2025 with $205 million in cash, cash equivalents and investments, and reduced operating expenses by 30% year-over-year. This positions the company with an operating runway through year-end 2027 to support ongoing clinical and collaboration milestones.
2. FT819 Phase 1 Enrollment and Outpatient Milestone
The FT819 off-the-shelf CAR T-cell program expanded its multi-center Phase 1 basket trial to 16 sites across the U.S., U.K. and EU, enrolling 15 SLE, four systemic sclerosis and one idiopathic inflammatory myopathy patient by February 25. The company achieved a key outpatient dosing milestone, administering FT819 without extended hospitalization or conditioning chemotherapy.
3. FT836 Early Colorectal Cancer Activity
FT836, the MICA/B-targeted off-the-shelf CAR T-cell therapy, demonstrated early clinical activity in a colorectal cancer patient at the first dose level, with over 50% reduction in CEA levels and tumor shrinkage across all target lesions without conditioning chemotherapy.
4. Outlook and Next Milestones
Fate plans to initiate its first Phase 2 trial in lupus nephritis later this year and will provide further clinical, regulatory and operational updates in the second half of 2026.